These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 31166139)

  • 1. Nanomedicine as a future therapeutic approach for Hepatitis C virus.
    Abd Ellah NH; Tawfeek HM; John J; Hetta HF
    Nanomedicine (Lond); 2019 Jun; 14(11):1471-1491. PubMed ID: 31166139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
    Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
    J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C?
    Michielsen P; Ho E; Francque S
    Minerva Gastroenterol Dietol; 2012 Mar; 58(1):65-79. PubMed ID: 22419005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
    Asselah T; Marcellin P
    Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anti-hepatitis C virus strategy targeting host entry factor claudin-1].
    Fukasawa M
    Uirusu; 2015; 65(2):245-254. PubMed ID: 27760923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis, diagnosis and management of hepatitis C.
    Boyer N; Marcellin P
    J Hepatol; 2000; 32(1 Suppl):98-112. PubMed ID: 10728798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chronic hepatitis C virus infection: clinical picture and treatment possibilities].
    Annicchiarico BE; Siciliano M; Gasbarrini A
    G Ital Nefrol; 2012; 29 Suppl 54():S103-8. PubMed ID: 22388839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C virus management: potential impact of nanotechnology.
    Elberry MH; Darwish NHE; Mousa SA
    Virol J; 2017 May; 14(1):88. PubMed ID: 28464951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control.
    Larrubia JR; Moreno-Cubero E; Miquel J; Sanz-de-Villalobos E
    World J Gastroenterol; 2015 Mar; 21(12):3480-91. PubMed ID: 25834312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C therapy: Looking toward interferon-sparing regimens.
    Au TH; Destache CJ; Vivekanandan R
    J Am Pharm Assoc (2003); 2015; 55(2):e72-84; quiz e85-6. PubMed ID: 25658389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization.
    Vercauteren K; Mesalam AA; Leroux-Roels G; Meuleman P
    World J Gastroenterol; 2014 Nov; 20(43):15975-91. PubMed ID: 25473151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asunaprevir-containing regimens for the treatment of hepatitis C virus infection.
    Yang SS; Kao JH
    Expert Rev Gastroenterol Hepatol; 2015 Jan; 9(1):9-20. PubMed ID: 25174254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Future perspectives: towards interferon-free regimens for HCV.
    Gane E
    Antivir Ther; 2012; 17(6 Pt B):1201-10. PubMed ID: 23186654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addressing the Challenges of Hepatitis C Virus Resistance and Treatment Failure.
    Colpitts CC; Baumert TF
    Viruses; 2016 Aug; 8(8):. PubMed ID: 27537906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel therapeutic approaches for hepatitis C.
    Au JS; Pockros PJ
    Clin Pharmacol Ther; 2014 Jan; 95(1):78-88. PubMed ID: 24126682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets.
    Ploss A; Dubuisson J
    Gut; 2012 May; 61 Suppl 1():i25-35. PubMed ID: 22504917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [HCV entry as a new therapeutic target in chronic hepatitis C].
    Dabrowska MM; Panasiuk A; Flisiak R
    Pol Merkur Lekarski; 2009 Aug; 27(158):140-3. PubMed ID: 19856882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extrahepatic manifestations of HCV: the role of direct acting antivirals.
    Polo ML; Laufer N
    Expert Rev Anti Infect Ther; 2017 Aug; 15(8):737-746. PubMed ID: 28696154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection.
    Sagnelli E; Pisaturo M; Martini S; Sagnelli C; Filippini P; Coppola N
    Expert Opin Pharmacother; 2014 Jul; 15(10):1337-49. PubMed ID: 24773464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals.
    Akuta N; Kobayashi M; Suzuki F; Sezaki H; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
    Oncology; 2016; 91(6):341-347. PubMed ID: 27694754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.